Search Videos and More

Showing 469 - 480 of 552 results

Previous| 1... 39 | 40 | 41 ...46 |Next


Bladder Cancer Research at ESMO Video

Bladder Cancer Research at ESMO

Dana-Farber's Guru Sonpavde, MD, provides insight on circulating tumor DNA trial in bladder cancer highlighted at ESMO 2021.
Kidney Cancer Research at ESMO Video

Kidney Cancer Research at ESMO

Dana-Farber's Toni Choueiri, MD, provides insight on KEYNOTE-564 trial in kidney cancer highlighted at ESMO 2021.
Benefit of Immunotherapy Combination for Patients with Advanced Melanoma Extends to Subsequent Treatment, Study Finds News

Benefit of Immunotherapy Combination for Patients with Advanced Melanoma Extends to Subsequent Treatment, Study Finds

A combination of two immunotherapy drugs, already shown to be more effective in patients with advanced melanoma than one of the drugs alone, also prolongs the benefit to patients who receive subsequent therapies, a clinical trial led by Dana-Farber Cancer Institute investigators indicates. The findings will be presented today at the 2021 Congress of the European Society of Medical Oncology (ESMO).
Antibody-Drug Conjugate Shows Impressive Activity in Patients with Non-Small Cell Lung Cancer with Mutation in HER2 Gene News

Antibody-Drug Conjugate Shows Impressive Activity in Patients with Non-Small Cell Lung Cancer with Mutation in HER2 Gene

More than half of patients with non-small cell lung cancer (NSCLC) bearing a mutation in the HER2 gene had their tumors stop growing or shrink for an extended time after treatment with a drug that hitches a chemotherapy agent to a highly targeted antibody, an international clinical trial led by investigators at Dana-Farber Cancer Institute has found.
Researchers Set Sights on New Ovarian Cancer Treatment Strategies News

Researchers Set Sights on New Ovarian Cancer Treatment Strategies

Despite breakthrough treatments for high-grade serous ovarian cancer, about 80 percent of patients relapse within two years, often resistant to treatment. The good news is that Dana-Farber scientists are pursuing multiple avenues of research that very well may improve outcomes.
Five Dana-Farber Cancer Institute Faculty Members are Inducted in the 2021 Giants of Cancer Care<sup>®</sup> News

Five Dana-Farber Cancer Institute Faculty Members are Inducted in the 2021 Giants of Cancer Care®

Five Dana-Farber Cancer Institute faculty members are inductees of the 2021 Giants of Cancer Care® program.
New Research Initiative Launches for All Patients Ever Diagnosed with Colorectal Cancer News

New Research Initiative Launches for All Patients Ever Diagnosed with Colorectal Cancer

Count Me In, a nonprofit cancer research initiative, is inviting all patients across the United States and Canada who have ever been diagnosed with colorectal cancer to participate in research and help drive new discoveries related to this disease.
Dosing Strategies Help Personalize Care in HER2+ Breast Cancer News

Dosing Strategies Help Personalize Care in HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH, discusses progress made with escalation and de-escalation strategies in HER2-positive breast cancer, ongoing research with immunotherapy, and efforts being made to further move the needle forward.
Season 1, Episode 4: The Blueprints of Your Cells Podcast

Season 1, Episode 4: The Blueprints of Your Cells

There are approximately 20,000 genes in the human genome. 20,000 packets that house the blueprints for every human cell. And every cell contains a complete copy of that genome.
Season 1, Episode 3: A Culture of Mentorship Podcast

Season 1, Episode 3: A Culture of Mentorship

What do cancer researchers and 15th century Florentine masters have in common? For one, a culture of mentorship. Both come of age in a culture where knowledge is transmitted from master to pupil. In this episode, we take a closer look at that culture and the crucial role mentorship plays at Dana-Farber, with Nobel laureate Dr. William Kaelin.
Triplet Therapy Shows Promise in Phase 2 Study in Chronic Lymphocytic Leukemia News

Triplet Therapy Shows Promise in Phase 2 Study in Chronic Lymphocytic Leukemia

Dana-Farber researchers find that combining a BCL-2 inhibitor with two other targeted agents is active in previously untreated CLL patients.
News

Dana-Farber Research Publication, 9.1.2021


Showing 469 - 480 of 552 results

Previous| 1... 39 | 40 | 41 ...46 |Next